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Abstract
Background: Chronic venous insufficiency is a serious disease for which there is no clearly
successful surgical treatment. Availability of a proven prosthetic vein valve could provide such an
option by reducing venous reflux while permitting normal antegrade flow.
Methods: A new prosthetic vein valve design has been developed which mimics the function of a
natural valve by ensuring complete closure of the leaflets with minimal obstruction for antegrade
flow. A 2:1 mock-up of the device was tested to evaluate its ability to prevent regurgitation and
several key modifications were made. A subsequently re-designed 1:1 prototype was then built in
4 slightly different size configurations and then each tested under physiologic conditions of pulsatile
flow in both supine and standing positions.
Results: Each of the configurations showed acceptable amounts of antegrade resistance and
effective orifice area and showed low values of regurgitation and % reflux with two of the prototype
configurations (flange lengths of 2.5 mm and 3.75 mm) having corresponding values of <2.5 mmHg-
min/L, >97%, 11 mL, and 36%, respectively. These values are particularly striking when compared
to the corresponding regurgitation and % reflux values of 60 mL and 205%, respectively, when no
device is present.
Conclusion: The results of this study show that this prototype vein valve design is capable of
providing significant relief of reflux under realistic conditions without inducing any increase in
antegrade flow resistance and warrants further testing with in vivo models.
Background
In the United States, chronic venous insufficiency (CVI)
afflicts ten to thirty-five percent of the adult population to
some extent [1] and is the seventh most common chronic
debilitating disease [2]. Ulceration associated with CVI
occurs at a rate of up to one and a half percent and in four
percent of patients over sixty-five years of age in industri-
alized populations [2]. CVI is distinguished from other
chronic venous disorders by a variety of alterations of the
skin due to prolonged venous hypertension [3]. Incompe-
tent venous valves directly result in reflux, which in turn
produces hypertension and causes the most serious symp-
toms of CVI including ulcers [4]. Increasing venous reflux
and decreasing calf muscle pump ejection fraction have
been shown via air plethysmography to be related to the
incidence of ulceration [5].
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Current CVI management strategies include external com-
pression devices, intermittent pneumatic compression,
other adjuvants (including dressings and skin substi-
tutes), and drugs while surgical alternatives include but
are not limited to ligation and stripping, thermal ablation,
sclerotherapy, valvuloplasty, and venous segment transfer
[6]. However, non-operative therapies remain the primary
treatment for CVI and ulceration [7]. Unfortunately, non-
operative techniques are only palliative in that they make
the symptoms of CVI tolerable while not treating the
underlying cause of the disease (i.e. venous reflux and
hypertension).
It is believed that a prosthetic venous valve is capable of
restoring normal hemodynamics as an alternative to sur-
gery or for those patients without surgical options. Cur-
rently, there are no commercially available prosthetic
venous valves as previous efforts have been hampered by
late failure and biocompatibility issues [8]. To date, only
two independently designed bioprosthetic valves have
undergone clinical trials [9-12] although several others
have been evaluated in vitro and in animal models.
Wang et al. [13] were among the first to create and test
bioprosthetic vein valves when they mounted bovine jug-
ular valves in straight, tapered, and curved conduits. The
devices were evaluated in an in vitro system where it was
determined that different pulse pressure thresholds were
necessary to "reestablish the CO [closure opening] opera-
tion mode" for each conduit geometry. Similarly, Delaria
et al. [14] evaluated fresh and glutaraldehyde fixed bovine
jugular vein conduits in an in vitro flow system and deter-
mined that the performance of the two valves is similar
while fixation theoretically renders biocompatible and
nonthrombogenic tissue. Therefore, it was suggested that
when mounted and stented, a glutaraldehyde fixed valve
has the potential to be the first clinical solution to CVI.
The most extensive work was performed by Pavcnik et al.
[15-21] who iterated on a bioprosthetic venous valve con-
sisting of a small intestinal submucosa (SIS) leaflet mate-
rial sutured to an expandable square stainless-steel wire
stent. The device featured sinuses and barbs for vascular
wall anchoring and was designed to be deployable via
catheter. Wire thickness determined valve size and expan-
sile force where ideal geometry was determined by con-
straining the diagonal axis of the square stent to a length
of πr based on a vessel circumference of 2πr [15]. When
implanted in an ovine external jugular vein model, the
valve restored antegrade circulation with little or no reflux
and the SIS leaflet was shown to undergo endothelializa-
tion, neovascularization, and incorporation into the
native vessel wall on the order of several months [18].
However, in several animals, tilting of the valves lead to
moderate reflux and thrombosis [18] prompting a sec-
ond-generation design that consisted of either a stainless-
steel stent attached to the apex of the original or a nonre-
strained nitinol double-stent [19]. The second-generation
design effectively corrected for valve misalignment; none-
theless, sizing with the nitinol version and intimal hyper-
plasia with the stainless-steel device caused dysfunction
[19]. A later study indicated that spatial orientation is
important and should correspond to that of the native
valve [20]. Although the previously described efforts by
Pavcnik et al. [21] have shown favorable in vivo results in
the short-term, a human feasibility study revealed that
occlusion occurred in four of fifteen valves at 12-month
follow-up. Additionally, three oversized valves opened
too much resulting in leaflet-to-wall attachment and four
devices exhibited undesirable leaflet pliability from
adverse healing. Hence, the potential for clinical applica-
tion of this bioprosthetic venous valve remains uncertain.
Work on synthetic valves has been more limited than
those of bioprosthetic design. A synthetic bileaflet valve
made of platinum or pyrolyte carbon covered titanium
was reported by Taheri and Schultz [22]. In nine canines,
the device restored retrograde flow and remained patent
in the short-term; however, within the initial three
months, two of the valves migrated or were misoriented
leading to failure. Within two years, all canines developed
symptoms of CVI due to intimal hyperplasia. Sathe et al.
[23] also created a synthetic venous valve, which is com-
posed of a clinically approved polymer.
The objectives of the subsequently described prosthetic
design were to preserve natural anatomic venous valve
features while improving upon a conceptual first-genera-
tion device described in a prior patent [24] for which no
quantitative testing was performed. The novel second-
generation design features are also presented in a patent
application currently under review [25].
Methods
From the natural anatomy, the most advanced second-
generation valve maintained sinus regions behind each of
two leaflets, which were in a normally open position. Pre-
served features from the first-generation design include
the integration of two distinct entities: a solid frame and a
flexible leaflet (Figure 1). More specifically, the frame con-
sists of a circular base from which two opposing struts
project proximally along the valve axis and where the flex-
ible leaflet is anchored. Novel features of the second-gen-
eration valve include the addition of inward directed
flanges to allow for precise matching of leaflet material to
closure path, a proximal leaflet contour to create a single
transverse plane of closure, shoulders on either side of the
struts for frame reinforcement and leaflet support, and a
beveled leaflet attachment surface that allows for the cre-BioMedical Engineering OnLine 2008, 7:25 http://www.biomedical-engineering-online.com/content/7/1/25
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ation of sinuses. Figure 1 defines the solid frame and flex-
ible leaflet for the second-generation design.
Frame design began by rendering the valve flange in two-
dimensions (in the transverse plane) followed by three-
dimensional axial contouring. Then, the frame geometry
was used to mathematically define a two-dimensional
leaflet template. Next, the frame and leaflet were fabri-
cated at a super-anatomic scale (2×) and a complete valve
created by wrapping the leaflet template around the
frame. The valve was then evaluated in a mock-up in vitro
flow system (2:1 dynamic scaling) and, based on perform-
ance, the need for two additional frame features was
defined: strut shoulders and a beveled leaflet attachment
surface. Finally, a matrix of devices from the most
advanced design were fabricated at anatomic scale (1×)
and evaluated in a physiologically-based, in vitro flow sys-
tem (1:1 dynamic scaling).
a. Two-dimensional frame design in the transverse plane
Inward directed flanges were introduced to occupy space
in the transverse plane such that the frame base circumfer-
ence exactly matches the leaflet closure path ensuring that
pleating or gapping does not occur upon leaflet closure.
One flange geometry fit this criterion while providing
gradual curves and a simple mathematical relationship
from which to design. In this configuration, each flange
consists of two half-circles connected by two inverted
quarter-circles of the same radius, which converge to a
point directed towards the valve lumen. At the points
where the flange intersects the frame base circumference,
the half circles are connected with a straight line produc-
ing a flat flange "back". The point at which the flange back
and half circle met was constrained as tangent to the cir-
cular base.
A design equation was defined in which the frame base
circumference and the closure path were balanced. Utili-
zation of symmetry in the quarter-plane resulted in:
where R = the valve radius,
r = the flange radius, and
Q = a constant that compensates for the flat flange back
and tangent point.
When Q equals r, the distance along a line from the cen-
tral valve lumen and perpendicular to the flat flange back
(subsequently labeled the y-axis) is exclusively dependent
on the flange geometry and independent of the valve
radius, R. Hence, Q cannot equal r and solution requires
a second design equation that is obtained by applying the
Pythagorean Theorem to the variables already defining
the frame. The second design equation is:
R2 = r2 + (3r + Q)2 (2)
ππ Rr
rQ
2
3
2
=+ + (1)
The two main components of the novel, second-generation  design: a solid frame and a flexible leaflet Figure 1
The two main components of the novel, second-gen-
eration design: a solid frame and a flexible leaflet. The 
threaded adaptor extension used to improve alignment and 
prevent leakage during in vitro testing is shown distal to the 
lower line. (2× scale model).
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(Figure 2 depicts the frame geometry and design relation-
ships in the transverse plane.) Choosing a valve radius of
R = 6.25 mm based on observations from a normal volun-
teer study performed by our group [26] allowed Equations
1 and 2 to be solved simultaneously. For R = 6.25 mm, it
was found that r = 1.37 mm and Q = 1.98 mm.
A minor limitation of the frame design is that the base cir-
cumference side of Equation 1 does not take the flat flange
back into account. Nonetheless, this assumption results in
an error of approximately 1E-5 mm for the quarter-plane
closure path, which is not considered significant.
b. Three-dimensional frame design
With design in the transverse plane finalized, the flange
geometry was then extended into a three-dimensional
object with the goal of optimizing hemodynamics and
biocompatibility. More specifically, zones of stasis and
excessive local shear stress were intended to be dimin-
ished along the flange such that thrombus formation and
blood damage would be minimized. Additionally, it was
recognized that flange contouring has the potential to
limit pressure drop and thus, minimize resistance. There-
fore, the flanges were extruded with minimal slope dis-
continuities in the axial direction and tapered at their
proximal and distal ends.
c. Leaflet design
Based on the second generation frame, leaflet design con-
siderations were defined in anticipation of future in vivo
application. For example, it was desirable to minimize
material surface area to limit thrombogenicity. Further, it
was important to decrease leaflet flexion angle because the
proximal base edge is a high stress region and thus, would
be the first area to fatigue from cyclic loading. Unfortu-
nately, these criteria work opposite to one another in that
decreasing the angle of leaflet closure (i.e. decreasing
cyclic stress) requires axial lengthening of the flange and
therefore, increasing surface area. Given the aforemen-
tioned considerations, it was useful to create a design con-
straint whereby all points of the proximal leaflet edge are
required to coapt in a single transverse plane. Such a clo-
sure plane was defined to be at the midpoint of the flange
and allowed the frame and leaflet surface areas to be min-
imized for a specific flange length.
However, the first step in implementing the desired
design feature was to define a three-dimensional Carte-
sian coordinate system based upon the optimized frame
design. The establishment of such a coordinate system
allows all points of the frame base circumference and clo-
sure path to be defined relative to one another in three-
dimensions. The reference planes were logically assigned
relative to the frame geometry. More specifically, the xy-
plane is parallel to the transverse plane where the x-axis is
directed towards the flange back and the y-axis towards
the valve sinus. The z-axis is perpendicular to the xy-plane
and follows the axis of the valve lumen. The point (0,0,0)
is defined to be on the valve axis in the xy-plane and at the
proximal base edge in the yz- or xz-planes. Figure 3 shows
the three-dimensional coordinate system with respect to
the second-generation frame.
Next, the frame was viewed in the xy-plane and points
from the radial edge of the base were mapped to their cor-
responding points on the flange during full closure using
a spreadsheet program (Microsoft Excel, Microsoft Corpo-
ration, Redmond, WA). In two-dimensions, the distance
between these points is the minimum length the leaflet
needs to have to guarantee full closure. For the mathemat-
ical details of the point mapping, see the Appendix.
Finally, the minimum leaflet length that guarantees full
closure was calculated as the three-dimensional resultant
of the point on the radial base edge to its corresponding
point in the closure plane. This was done using the previ-
Geometric relationships and frame design equations in the  transverse plane Figure 2
Geometric relationships and frame design equations 
in the transverse plane. Equation 1 is represented on the 
left where it is the goal to match the valve circumference 
(green) to the closure path (red). Equation 2 is represented 
on the right where the objective is to compensate for the flat 
flange back and tangent point. When solved simultaneously, 
the system provides a solution for both the flange radius, r, 
and Q where the valve radius, R, is the independent parame-
ter.
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ously described three-dimensional mapping techniques
and the following relationship:
where L = the minimum length of the leaflet for full clo-
sure
The valve base height was added to L and provided an
overlap between frame and leaflet for the application of
adhesive.
The tabulation of corresponding values of X and L pro-
vides a series of data points that create one-quarter of a
two-dimensional leaflet template. When symmetry is uti-
lized and additions for the flange back are made, a com-
plete template is produced. The template creates a leaflet
when wrapped around the frame. Figure 5 is the leaflet
template as plotted by the spreadsheet program.
d. Fabrication
The completed valve prototype consists of a combination
of the solid frame and flexible leaflet. The frame was accu-
rately and precisely modeled using computer-aided
design (CAD) software (ProE 2000 i2, Product Develop-
ment Company, Needham, MA) and then fabricated with
stereolithography (SLA) rapid prototyping technology
that utilized a photo-activated polymer resin (RenShape®
SL 5210, Huntsman Advanced Materials, Salt Lake City,
UT) consisting of bis-(epoxycyclohexyl)-methylcarboxy-
late and 2,2-dimethoxy-2-phenylacetophenone. Upon
polymerization, residual resin was removed by submer-
sion in iso-propanol and further cured in a UV oven. The
leaflets, on the other hand, were created using a hand fab-
rication technique. The data points composing the leaflet
template were transferred to a different program (MAT-
LAB 6.5, The MathWorks Incorporated, Natick, MA) for
2D plotting. The axes were scaled equally for proportion-
ality and then printed on an 8.5 × 11.0 inch sheet of
paper. A copy machine (Canon NP6545, Canon Incorpo-
rated, Japan) was then used to reduce the template to a
size that corresponded to the valve frame. This size was
determined via trial and error and the best fit selected
based on circumference. For the mock-up valves (2×), the
scaling factor was found to be 54% whereas the proto-
types (1×) required a reduction of 50% followed by a sub-
sequent scaling of 57%. Once the proper size template
was acquired, the leaflet material was taped over the tem-
plate and the geometry of the leaflet traced on the material
using a black pen. For all created valves (both 2× mock-
ups and 1× prototypes), 5 mil (0.1270 mm) thick sheets
of BioSpan® (BioSpan®, Polymer Technology Group, Ber-
keley, CA) were used as the leaflet material upon which
reference lines for the flange back and proximal base edge
were also drawn. The leaflet was then cut out using a sur-
LX xY y Z z =− + − + − () () )
22 2 (10)
The three-dimensional Cartesian coordinate system utilized  for leaflet design Figure 3
The three-dimensional Cartesian coordinate system 
utilized for leaflet design.
 
Cartesian definitions for point mapping and leaflet design in  the transverse plane Figure 4
Cartesian definitions for point mapping and leaflet 
design in the transverse plane.
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gical scalpel and super-glue was applied to the portions of
the leaflet that were to meet on the flange back and below
the proximal base edge. Finally, the leaflet was attached to
the frame by approximating the center of the leaflet to the
flange back and then rolling the valve in either direction
to evenly wrap the remainder of the leaflet around the
frame base.
e. 2:1 mock-up, in vitro flow system and design 
modifications
After completing the initial design, the valve was fabri-
cated at 2× scale and inserted into an in vitro flow loop fea-
turing a vertical column, steady flow system with water as
the test fluid as previously described by our group [26].
Dynamic similarity was maintained from the 1× scale
with the goal of studying leaflet-frame interaction under a
uniform reversing pressure. Three observations were
made that warranted further development of the second-
generation design: 1) the leaflets only closed under a
physiologically analogous reversing pressure gradient
when they were artificially drawn off the tube wall, 2) an
undesirable sagging of the closed leaflets was observed in
the yz-plane, and 3) the frame was susceptible to breaking
where the flanges intersect the proximal base edge when
subjected to a bending stress. The first issue was addressed
by creating a bevel on the proximal base edge from which
the leaflets were adhered that also produced a sinus
behind each leaflet. The other two problems were resolved
with the addition of a supporting "shoulder" that inter-
sects the flange at the closure plane (when viewed in the
yz-plane). In the xy-plane, the shoulder followed the
proximal base edge, but did not protrude into the valve
lumen. The proximal edge of this shoulder was antici-
pated to support the leaflet during closure while the
remainder of the structure reinforces the flange. Corre-
spondingly, the leaflet design spreadsheet was changed to
accommodate the new geometries. The evolution of the
bevel and shoulder features is shown relative to the origi-
nal second-generation frame design in Figure 6.
f. Design matrix
The aforementioned methodology addresses the issues of
conserving leaflet and flange material by defining a single
closure plane; however, varying the angle of leaflet flexion
and sinus volume was not addressed. Nonetheless, it was
recognized that the generic design could be dimensionally
modified to accommodate such considerations. A single
feature of the flange was identified that influenced both
leaflet flexion angle and sinus size and was referred to as
the flange length (FL). Physically, the FL was described as
the distance in the z-direction between the tapered tips of
the fully developed flange. Four different flange lengths
were chosen: 1.25, 2.50, 3.75, and 5.00 mm, which had
the effect of varying the leaflet flexion angle in a linear
range from 38.7 to 11.3°, respectively.
g. 1:1 physiologically-based, in vitro flow system
After the addition of the bevel and shoulder features, the
prototypes were fabricated at 1× scale with threading at
the distal end to allow reproducible insertion into the
The 2-D leaflet template with L plotted versus X by the spreadsheet program Figure 5
The 2-D leaflet template with L plotted versus X by the spreadsheet program.
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The original (left) and most advanced (right) second-generation frames as depicted in the yz- (top) and xz- (bottom) planes Figure 6
The original (left) and most advanced (right) second-generation frames as depicted in the yz- (top) and xz- 
(bottom) planes. The additional bevel and shoulder features of the most advanced design are labeled and indicated with 
arrows.
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physiologic in vitro flow model as described by our group
[26]. A blood analog test fluid consisting of 3.45% dex-
tran (Sigma-Aldrich Corporation, St. Louis, MO) in dis-
tilled water was utilized where the viscosity was 3.5 cP.
The testing protocol and parameters of interest were pre-
served from the prior study although a less detailed review
is concurrently presented.
The in vitro flow model was designed to simulate any com-
bination of two body positions (supine and standing) and
two dynamic conditions (breathing and ankle flexion).
Therefore, a total of four simulations are possible: supine
breathing (SUBR), standing breathing (STBR), supine
ankle flexion (SUAF), and standing ankle flexion (STAF).
Body position was controlled via hydraulic communica-
tion between hydrostatic pressure towers and the test sec-
tion while dynamic condition was determined via the
frequency of flow pulsatility provided by a roller pump. A
"No Device" case was run in an attempt to simulate the
dynamic conditions of CVI in which the valve system is
compromised. As the nomenclature indicates, the "No
Device" case consisted of executing the test protocol with-
out a device in place where a completely open orifice
existed and the system was sealed around the threaded
adaptor. The "No Device" case was used to calculate the
experimentally determined Effective Orifice Area (EOA)
coefficient, Cd, appropriate for these conditions where the
open orifice area was directly measured and Qrms and ΔP
were obtained from sampled data [26]. Cd values of 2.32
± 0.030 and 6.38 ± 0.142 cm.mmHg1/2.s-1 were obtained
for the SUBR and SUAF simulations, respectively.
Sampled data included differential pressure and flow rate
waveforms (Figure 7) from which Resistance, EOA, Regur-
gitation, Percent Reflux, Reflux Energy Loss (REL), Ante-
grade Energy (AE), and Energy Retention parameters were
calculated as defined in our prior manuscript [26].
Beyond the parameter definitions that are standard for
cardiac valves (Resistance, EOA, and Regurgitation), Per-
cent Reflux, REL, AE, and Energy Retention were devel-
oped specifically for the evaluation of venous valves.
Briefly, Percent Reflux is the ratio of retrograde to ante-
grade volume, REL is the energy necessary to re-pump the
reflux volume through the valve, AE quantifies the energy
produced by the pump to propel the fluid proximally, and
Energy Retention compares REL to AE. All values are based
on five cycle periods and are presented as means ± stand-
ard deviation.
h. Statistical methods
Since there currently exists no clinically approved 'de facto'
standard device for comparison, it was hypothesized that
the second-generation prototypes would significantly
improve systemic level hemodynamics (as characterized
by the Regurgitation, Percent Reflux, REL, AE, and Energy
Retention parameters) when compared to the CVI simu-
lated "No Device" case. Additionally, it was theorized that
differing FLs lead to unique in vitro dynamic performance
for each parameter. Statistical analysis of design matrix
data consisted of a one-way analysis of variance (ANOVA)
followed by post hoc SNK or Dunnet T3 procedures for
equal and unequal variances, respectively. A comparison
of duplicate prototypes of the same design utilized a series
of independent-samples t-tests. Both statistical analyses
were performed using a commercially available software
package (SPSS 14, SPSS Incorporated, Chicago, IL) with a
significance level of 0.05.
Results
a. 2:1 mock-up, in vitro flow system
Although data was collected as part of mock-up testing,
those results are not presented because the developmental
value of the simulation was primarily qualitative. How-
ever, as previously described, mock-up testing resulted in
the addition of the shoulder and bevel features, which
provided leaflet support and created sinuses, respectively.
It was found that sinuses are crucial for valve actuation
upon venous diastole (a retrograde pressure gradient).
b. 1:1 physiologically-based, in vitro flow system
Data characterizing antegrade hemodynamic device per-
formance is presented in Figure 8. For the supine position
simulations, the devices with FLs of 1.25 and 2.50 mm
statistically had the lowest Resistance with both achieving
around 0.50 and 1.0 mmHg.min/L for the SUBR and
SUAF simulations, respectively. With regard to EOA,
devices with FLs of 1.25 and 2.50 mm exhibited statisti-
cally superior EOA performance with approximately 1.2
cm2 for both simulations. The "No Device" Resistance was
defined as 0 mmHg.min/L whereas the "No Device" EOA
was calculated as the cross-sectional area of the open tube.
Hence, the "No Device" Resistance and EOA were not
included in the ANOVA and the corresponding grouping
nomenclature is different from that of the other parame-
ters.
Data characterizing retrograde hemodynamic device per-
formance is presented in Figure 9. With regard to the
standing position simulations, all devices statistically
improved retrograde hemodynamics relative to the "No
Device" case. More specifically, the FL 2.50 and 3.75 mm
valves statistically outperformed the other two devices in
the standing position simulations for the Regurgitation,
Percent Reflux, and Reflux Energy Loss parameters. Also,
the FL 2.50 and 3.75 mm devices demonstrated favorable
performance for the Energy Retention parameter in the
STBR simulation. Further, the Antegrade Energy data for
the STBR simulation all belong to the same statistical
grouping, which includes the "No Device" case. For the
STBR simulation, the FL 2.50 and 3.75 mm prototypesBioMedical Engineering OnLine 2008, 7:25 http://www.biomedical-engineering-online.com/content/7/1/25
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Representative differential pressure (top) and flow rate (bottom) waveforms from the physiologic system under the STBR con- dition utilizing a second-generation prototypic valve Figure 7
Representative differential pressure (top) and flow rate (bottom) waveforms from the physiologic system 
under the STBR condition utilizing a second-generation prototypic valve. The division of one cycle associated with 
the calculation of antegrade and regurgitant volumes is shown.
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demonstrated Regurgitation, Percent Reflux, Reflux
Energy Loss, and Energy Retention values around 11 mL,
36%, 9 mJ, and 87%, respectively, as compared to 60 mL,
205%, 283 mJ, and -319% for the "No Device" case,
respectively. Data from the STAF simulation were approx-
imately 2 mL, 6%, 0.5 mJ, and 99%, respectively, for the
FL 2.50 and 3.75 mm devices and 7 mL, 25%, 4 mJ, and
94%, respectively, for the "No Device" case.
As shown in Tables 1A and 1B for duplicates of the FL 2.50
mm design, intra-design variability in the supine position
simulations is statistically significant for all parameters
with the exception of SUAF EOA. For the standing posi-
tion simulations, intra-design variability is statistically sig-
nificant for all parameters. Multiple prototypes of the FL
5.00 mm design were also created, which show significant
differences only for the SUBR Resistance and STAF REL
parameters (data not presented).
Discussion
a. Comparison with other studies
Several other published reports utilize similar hemody-
namic conditions and parameters for evaluating pros-
thetic vein valves. More specifically, Delaria et al. [14]
presented EOA data for fresh and fixed bioprosthetic
valves with values around 1.1 and 0.70 cm2, respectively,
at flow rates of 0.5 and 1 L/min. The fixed valves (that
were suggested as most appropriate for native replace-
ment) have smaller EOAs than the second-generation pro-
totypes for which values of approximately 1.1 cm2 were
obtained for the SUAF simulation where the steady com-
ponent flow rate was 0.75 L/min. However, for these bio-
prosthetic devices, EOA data was obtained by a visual
method while it was calculated as a function of pressure
and flow for our second generation valves. Delaria et al.
also presented several cycles of a waveform that show
reversing flow.
Means, standard deviations, and statistical groupings for Regurgitation, Percent Reflux, Reflux Energy Loss, and Energy Reten- tion (parameters characterizing retrograde device performance) for the FL 1.25–5.00 mm prototypes Figure 9
Means, standard deviations, and statistical groupings for Regurgitation, Percent Reflux, Reflux Energy Loss, 
and Energy Retention (parameters characterizing retrograde device performance) for the FL 1.25–5.00 mm 
prototypes. Values for the "No Device" case for each simulation are presented as part of the x-axis label. Alphabetical labels 
denote groups that are statistically different from each other (p < 0.05). By convention, the "No Device" case belongs to statis-
tical group A.
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Means, standard deviations, and statistical groupings for Resistance, EOA, and AE for the FL 1.25–5.00 mm prototypes Figure 8
Means, standard deviations, and statistical groupings for Resistance, EOA, and AE for the FL 1.25–5.00 mm 
prototypes. Corresponding values for the "No Device" case for each simulation are presented as part of the x-axis label. 
Alphabetical labels denote groups that are statistically different from each other (p < 0.05). By convention, the W-X-Y-Z 
grouping nomenclature (for Resistance and EOA) does not include the "No Device" case as part of the ANOVA whereas the 
"No Device" case is included in the ANOVA as statistical group A where A-B-C-D nomenclature is utilized (for AE).
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Pavcnik et al. [18-21] qualitatively described hemody-
namic performance of their bioprosthetic valve. More spe-
cifically, "minimal or no leak" was noted after immediate
venogram in twenty-four of twenty-five devices implanted
in porcine inferior vena cavas. Of twenty-six valves
implanted in ovines, twenty-five had "no reflux" on
immediate venography and twenty-two upon sacrifice
[18]. Two of the failed valves had "moderate reflux" at
three months. In another ovine trial, four valves from a
design array of forty-eight total valves had "significant
leak" at six-week follow up on venogram [19]. Further,
one of six orthogonally oriented valves "showed reflux"
on venography compared to none of the six in anatomic
orientation [20]. In patients, four of fifteen valves demon-
strated "moderate leak" on venograms and ultrasound at
twelve months [21].
With regard to prosthetic devices, Taheri et al. [22]
reported regurgitant flow of 145 mL/min for a valve sub-
jected to 300 mL/min of forward flow and back pressures
of 100 mmHg. Further, in vitro test results of the prosthetic
valve by Sathe et al. [23] showed that after more than
290,000 cycles the device had an opening pressure gradi-
ent of approximately 3 mmHg and a reflux rate of less
than 3 mL/min at a pressure of over 150 mmHg. The valve
was evaluated in an in vitro water system with a frequency
of 40 cycles/min and an average proximal hydrostatic
pressure of 65 mmHg. Unfortunately, the studies by
Taheri et al. and Sathe et al. cannot be directly compared
to each other or those of the second-generation proto-
types. Hence, standardization of testing conditions and
characterizing parameters are necessary as intended by
our prior publication [26] and extended in the current
manuscript.
b. Device performance in 1:1 physiologically-based, in 
vitro flow system
The data of Figures 8 and 9 demonstrate that the in vitro
flow system and corresponding parameters are capable of
quantifying hemodynamic improvement from the CVI
simulated "No Device" case relative to the second-genera-
tion prototypes. Also, the system is able to evaluate rela-
tive performance for device-specific selection as
previously indicated by repeat measurements of the FL
1.25 mm prototype [26]. However, intra-design variabil-
ity confounds design-specific selection, which is evident
Table 1: 
A Antegrade intra-design variability as indicated by evluation of duplicate prototypes from the FL 2.50 mm design.
SUBR STBR SUAF STAF
Device Resistance
(mmHg·min/L)
EOA
(cm2)
AE
(mJ)
Resistance
(mmHg·min/L)
EOA
(cm2)
AE
(mJ)
FL 2.50A 0.508 ± 0.041 1.18 ± 0.020 74.6 ± 5.12 0.878 ± 0.065 1.14 ± 0.018 78.3 ± 5.67
FL 2.50B 0.389 ± 0.046* 1.23 ± 0.024* 64.6 ± 5.00* 1.14 ± 0.208* 1.14 ± 0.045 92.1 ± 4.14*
Change 0.119 0.05 10.0 0.262 0.00 13.8
* p < 0.05 versus FL 2.50A
B Retrograde intra-design variability as indicated by evaluation of duplicate prototypes from the FL 2.50 mm design.
STBR
Device Regurgitation
(mL)
Percent Reflux
(%)
REL
(mJ)
Energy Retention
(%)
FL 2.50A 11.0 ± 0.258 35.8 ± 1.63 9.55 ± 0.078 87.1 ± 1.18
FL 2.50B 7.82 ± 1.17* 27.6 ± 5.10* 4.95 ± 1.44* 92.2 ± 2.77*
Change 3.18 8.20 4.60 5.10
STAF
FL 2.50A 2.19 ± 0.536 6.98 ± 1.71 0.400 ± 0.177 99.5 ± 0.227
FL 2.50B 6.06 ± 1.30* 17.8 ± 3.58* 3.02 ± 1.21* 96.7 ± 1.20*
Change 3.87 10.8 2.62 2.80
* p < 0.05 versus FL 2.50ABioMedical Engineering OnLine 2008, 7:25 http://www.biomedical-engineering-online.com/content/7/1/25
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by the current study and also by comparing the data of the
FL 1.25 mm prototype from our previous study [26] and
another device of the same design that is subsequently
presented. Therefore, the following selection process is
device-, but not design-specific with regard to the second-
generation prototypes.
c. Relative importance of simulation position/condition 
and parameters
Devices were evaluated utilizing four physiologically rele-
vant simulations by seven hemodynamic parameters
without a single device being superior on all measures.
Hence, selection must weigh the relative value of all
parameters and simulations.
For the supine position simulations, Resistance and EOA
were found to be significantly different from the "No
Device" case for the four designs. However, all values are
considered acceptable since they easily satisfied the
acceptable performance criteria established a priori –
namely, ΔP < 5 mmHg (≡ Resistance < 8.3 mmHg·min/L)
and EOA > 80% of 'No Device' case (= 0.984 cm2), verify-
ing that the devices did not notably impede antegrade
flow.
With regard to the standing position simulations, STBR is
the most demanding simulation for characterizing retro-
grade performance. This is because, in the STAF simula-
tion, the higher frequency of the pumping cycle acts as an
effective valve due to the reduced time available for the
flow momentum to reverse. Hence, parameters of the
STBR simulation are exclusively used in design selection.
When considering specific parameters, most include
reflux volume as an independent variable (with the excep-
tion of Antegrade Energy). As a result, there is inherent
redundancy in the characterization of retrograde perform-
ance, which diminishes the multi-dimensional utility of
the parameters in selection. Percent Reflux normalizes for
periodic variations in antegrade volume and therefore, is
reasoned as the only quantity necessary for selection of
the second-generation prototypes.
While only one simulation and one parameter are neces-
sary for device selection of the second-generation proto-
types, a different combination of simulations and
parameters may prove useful in distinguishing valves of
more dissimilar designs. Of anticipated future importance
are the Percent Reflux and Energy Retention parameters
because they provide meaningful performance bounda-
ries, which have physical significance. More specifically,
Percent Reflux can be considered a valve ejection fraction
where values greater than 100% are not possible and
those less than 0% indicate a positive fluid accumulation
in the distal venous space and CVI perpetuation. When
the valve is operating in a range from 0 to 100% reflux,
fluid accumulation in the distal venous space is negative
and the conditions of CVI are being alleviated. Similarly,
for the Energy Retention term, values less than 0% indi-
cate the valve is allowing the hydrostatic fluid column to
perform work on the calf muscle pump. Further, values
greater than 0% indicate that the valve is permitting the
energy exerted on the fluid from the calf muscle pump to
be retained in the form of hydrostatic potential energy;
hence, the term, Energy Retention. There is also an upper
limit of 100% for the Energy Retention parameter. All sec-
ond-generation prototypic, prosthetic valves perform in
the optimal ranges of Percent Reflux and Energy Retention
whereby the hemodynamics are favorable for CVI treat-
ment.
d. Selection
Based on their statistically superior performance as quan-
tified by the Percent Reflux parameter in the STBR simula-
tion, the most advanced second-generation valves
featuring FLs of 2.50 and 3.75 mm are superior to those of
1.25 and 5.00 mm. However, as previously described, this
selection is device- and not design-specific.
e. Frame design
A frame feature not evaluated via in vitro techniques and
thus, not described in the Methods section is the incorpo-
ration of drug delivery reservoirs within each flange of the
second-generation design. It is envisioned that the reser-
voirs communicate with the physiologic environment via
channels made of a rate controlling material. The chan-
nels are directed either towards the valve lumen to influ-
ence thrombosis or towards the vessel wall to limit
intimal hyperplasia and/or promote valve incorporation.
Multiple isolated reservoirs within each flange allow a sin-
gle device to contain more than one drug. In the single
and dual reservoir per flange configurations, it is esti-
mated that the reservoirs have volumes of 26.3 mm3 and
7.5 mm3, respectively. Therefore, the single and dual res-
ervoir configurations are estimated to have 56.6 mm3 and
30.2 mm3 of total volume per device, respectively. How-
ever, the approximations are based on the 3.75 mm FL
design and vary directly with FL. Figure 10 depicts both
the single and dual reservoirs with communicating chan-
nels. Also not evaluated by in vitro testing is a balloon
catheter deliverable configuration whereby the frame base
is composed of a radially expandable scaffold (similar to
a stent) and the symmetric flanges are mated prior to
deployment.
f. Future directions
Prospective development objectives include: 1) the selec-
tion of an appropriate biomaterial for the frame, and, 2)
casting BioSpan® in a mold for more precise proximal edge
contouring while scaling thickness for the 1× prototype
(2.5 mil/0.0635 mm). It is also desirable to improve theBioMedical Engineering OnLine 2008, 7:25 http://www.biomedical-engineering-online.com/content/7/1/25
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reproducibility of leaflet-to-frame attachment to mini-
mize intra-design variability. Finally, our group intends to
report a CFD study of local hemodynamics including wall
shear stress and residence time from the most advanced
second-generation design prior to assessing biocompati-
bility  in vivo utilizing an ovine external jugular vein
model.
Conclusion
Results indicate that the STBR simulation provided the
best means of discriminating among second-generation
valves of varying FLs. Further, only one parameter, Percent
Reflux, was appropriate for device selection. Statistical
analysis, revealed the 2.50 and 3.75 mm FL devices are
superior to those of 1.25 and 5.00 mm with a Percent
Reflux of 36%. However, intra-device and intra-design
variability confound design selection. Nonetheless, all
prototypic, prosthetic valves provided a dramatic and sta-
tistically significant improvement when compared to the
"No Device" case (Percent Reflux of 205%), which was a
simulated reference to the dynamic conditions of CVI.
This leads to the general conclusion that the most
advanced prototypic, prosthetic venous valve has the
potential to reestablish normal antegrade circulation.
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Appendix
Mathematically, the leaflet-closure plane point mapping
was accomplished by first defining a variable, Θoffset,
which is the angle formed by the x-axis, the origin, and the
tangent point where the flange back meets the half circle.
For the aforementioned optimized frame, Θoffset  was
found to be 12.7°. Then, the xy-coordinates of discreet
points on the radial base edge were determined by incre-
menting the angle from the x-axis by 0.25 radians and
applying the following equations:
X = R cosΘ (3)
Y = R sinΘ (4)
where X = the Cartesian coordinate of the radial base edge
from the x-axis,
Y = the Cartesian coordinate of the radial base edge from
the y-axis,
R = the valve radius, and
Θ = the angle from Θoffset in radians = angle – Θoffset.
Potential drug delivery reservoir (red) and channel configurations (yellow) as part of the most advanced second-generation  design Figure 10
Potential drug delivery reservoir (red) and channel configurations (yellow) as part of the most advanced sec-
ond-generation design.
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Then, points on the radial base edge were mapped to their
corresponding position on the flange using the following
relationship:
S = RΘ = rθ (5)
where s = arc length,
R = the valve radius,
Θ = the angle from a point on the valve edge to Θoffset in
radians,
r = the flange radius, and
θ = a reference angle corresponding to the mapped point
on the flange.
In Equation 5, R was set at 6.25 mm and the solution of
Equations 1 and 2 provided that r is 1.37 mm. Therefore,
because Θ was incremented, θ is the dependent variable.
Physically, θ is the angle formed by the θoffset reference
point, the origin, and a specific point on the flange. Anal-
ogous to the radial base edge, two-dimensional Cartesian
coordinates are found from the following equations:
x = r cos θ + x'( 6 )
y = r sin θ + y'( 7 )
where x = the Cartesian coordinate of the flange from the
x-axis,
y = the Cartesian coordinate of the flange from the y-axis,
r = the flange radius,
θ = a reference angle corresponding to the mapped point
on the flange,
x' = the x displacement of one flange circle, and
y' = the y displacement of the same flange circle.
The displacements are necessary because the points com-
posing the flange are based on circles that have different
centers. Thus, for the portion of the flange composed of
the half-circle, x' equals (2r + Q) and for this specific
design is 4.71 mm. Similarly, y' is r or 1.37 mm. For the
quarter-circle portion, x' is Q or 1.97 mm and y' is r or
1.37 mm. The line connecting the tip of the flange and the
origin is linear and therefore, requires a separate mathe-
matical definition for mapping the remaining arc length
of the radial base edge. These points were evenly distrib-
uted along the remainder of the closure path, which com-
pleted the two-dimensional considerations. Figure 4
depicts the Cartesian definitions for leaflet design in the
transverse plane.
To resolve the coordinates in the third dimension, the
frame was viewed in the yz-plane and the displacement in
the z-direction was determined. For the radial base edge,
the z-coordinate is zero by definition of the origin. Simi-
larly, by design constraint, the z-coordinates of the closure
plane all have a constant value. Staying consistent with
nomenclature in the xy-plane, these relationships were
expressed mathematically as:
Z = 0 (8)
z = H (9)
where Z = the Cartesian coordinate of the radial base edge
from the z-axis,
z = the Cartesian coordinate of the flange from the z-axis,
and
H = the predetermined leaflet closure height.
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